How Is LDL Cholesterol Calculated?

Most of the time, the LDL cholesterol number on your lab report is not directly measured. It is calculated from three other values your blood test does measure: total cholesterol, HDL cholesterol, and triglycerides. The formula used in most labs worldwide dates back to 1972 and works well for many people, but it has blind spots that matter most in exactly the patients who need the most accurate numbers. Understanding how the calculation works, where it breaks down, and what alternatives exist can help you make sense of your own results.

The Friedewald Formula

When you get a standard lipid panel, the lab measures your total cholesterol, HDL cholesterol, and triglycerides directly. LDL cholesterol is then estimated by subtraction. The Friedewald equation, introduced in 1972, says: LDL cholesterol equals total cholesterol minus HDL cholesterol minus triglycerides divided by 5 (when everything is measured in mg/dL).¹ The logic is straightforward: the cholesterol in your blood is carried by different types of particles, and if you know the total amount, subtract the portion carried by HDL, and subtract an estimate of the portion carried by VLDL (the triglyceride-rich particles), what remains is roughly the LDL cholesterol.

The “divide triglycerides by 5” step is the formula’s key assumption. It estimates how much cholesterol is riding around in VLDL particles by assuming that VLDL cholesterol is always about one-fifth of the triglyceride level. For people with triglycerides in a normal range, this ratio holds up reasonably well. The equation became the global default because it is cheap, requires no additional reagents, and can be done with a basic lipid panel. Decades of clinical research, treatment guidelines, and drug trials have been built on Friedewald-calculated LDL values.

Where the Classic Formula Gets It Wrong

The one-fifth assumption is an average. It does not account for the fact that the ratio of triglycerides to VLDL cholesterol varies from person to person and changes depending on triglyceride levels. The Friedewald equation uses a fixed divisor, which means it does not reflect individual variability, and this often leads to underestimation of LDL cholesterol.² The original authors themselves recognized that inaccuracies would grow at lower cholesterol concentrations and higher triglyceride levels, because the VLDL estimate makes up a larger share of the math and errors in it distort the final LDL number more.³

In practice, this means the Friedewald formula tends to underestimate LDL when LDL is genuinely low. One study of patients undergoing LDL apheresis found the negative bias grew progressively worse as LDL dropped: about 4% at higher LDL concentrations, climbing to roughly 19% at the lowest levels.⁴ A large analysis comparing Friedewald values against ultracentrifugation (the gold-standard lab method) found that when calculated LDL was below 40 mg/dL, roughly 60% of those values were discordantly low, meaning the person’s true LDL was higher than the formula suggested. At the very lowest calculated values, below 15 mg/dL, discordance reached about 95%.⁵

High triglycerides compound the problem. When triglycerides are at or above 150 mg/dL, the Friedewald equation commonly labels patients as having LDL below 70 mg/dL even though their directly measured LDL is at or above that cutoff.⁶ This is a real clinical problem because 70 mg/dL is the treatment target for many high-risk patients. If the formula says you are below goal when you are not, your doctor may not intensify your medication when they should. The Friedewald equation is also considered unreliable when triglycerides exceed 400 mg/dL, and most labs will not even report a Friedewald-calculated LDL in those cases.

Newer Calculation Methods

Recognizing the Friedewald formula’s weaknesses, researchers have developed updated equations. The two most prominent are the Martin-Hopkins equation and the Sampson-NIH equation (sometimes called “NIH equation 2”). Both attempt to improve accuracy in the situations where Friedewald performs worst: low LDL and elevated triglycerides.

The Martin-Hopkins equation, published in 2013, replaces the fixed divisor of 5 with an adjustable factor pulled from a table of 180 different values. The right factor is selected based on the patient’s specific triglyceride and non-HDL cholesterol levels. This patient-specific approach makes the VLDL estimate more accurate for people who don’t fit the average ratio. A meta-analysis found that the Martin-Hopkins formula was especially more accurate than Friedewald in patients with triglycerides above 200 mg/dL or LDL below 70 mg/dL.⁷ In the ultracentrifugation comparison study mentioned earlier, when true LDL was 25 to 40 mg/dL, the Martin-Hopkins equation cut the rate of discordantly low results roughly in half compared with Friedewald.⁵

The Sampson-NIH equation, published in 2020, takes a different approach. It uses a regression-based formula with triglycerides and non-HDL cholesterol as inputs and was designed to remain accurate even when triglycerides run between 400 and 800 mg/dL, a range where Friedewald is usually not attempted at all. Compared against ultracentrifugation, the Sampson equation was substantially more accurate than both Friedewald and Martin-Hopkins in patients with very high triglycerides, with about 35% fewer misclassifications into wrong treatment categories.⁸

That said, none of these formulas are perfect at extremely high triglyceride levels. In patients with triglycerides above roughly 400 mg/dL, even the Martin-Hopkins and Sampson equations miscategorize about a third of patients into the wrong treatment group when compared to direct measurement.⁹ The improvement is real but not a complete fix. In a pooled analysis of large trials using the drug alirocumab, all three equations showed strong correlations with ultracentrifugation-determined LDL, and at LDL levels of 70 mg/dL or above, misclassification rates were low for all methods: about 3% for Friedewald, under 2% for Martin-Hopkins and Sampson.¹⁰ In other words, when LDL and triglycerides are both in moderate ranges, the equations agree closely and the choice between them matters less.

Direct Measurement and the Gold Standard

Instead of calculating LDL from other lipid values, labs can measure it directly using what are called homogeneous assays. These are automated, commercially available tests that use detergents and enzymes to selectively measure cholesterol carried by LDL particles, without needing to physically separate them. For routine samples, these direct assays meet precision and accuracy standards set by guideline groups, typically with less than 4% variability.¹¹ In healthy individuals, direct assays from multiple manufacturers showed excellent consistency, with the maximum variability between runs staying around 2% or less.¹²

However, direct assays have their own limitations. That same multicenter study found that in patients with conditions like high triglycerides, diabetes, or kidney disease, some direct-assay reagents produced results that overestimated LDL compared to ultracentrifugation, and fewer reagents met accuracy standards in these “diseased” samples than in healthy ones.¹² Different manufacturers’ reagents can give noticeably different results for the same sample, which means “direct LDL” is not one uniform test.

The true gold standard for LDL measurement is a laboratory technique called beta-quantification, which uses an ultracentrifuge to physically separate lipoproteins by density and then measures the cholesterol in each fraction. This method, maintained by the CDC and the Cholesterol Reference Method Laboratory Network, is considered the highest-order reference procedure for LDL cholesterol.¹³ It is too slow and expensive for routine clinical use, so it serves as the benchmark against which all calculations and direct assays are judged. Even beta-quantification is itself a calculation: it measures the cholesterol in the bottom fraction of the centrifuge tube and subtracts HDL cholesterol to arrive at LDL.

Does Fasting Still Matter?

Triglycerides rise after eating, and since the Friedewald formula uses triglycerides as a key input, fasting has traditionally been required for accurate LDL calculation. If you eat a fatty meal before your blood draw, your triglycerides spike, the VLDL estimate balloons, and the formula subtracts too much, yielding a falsely low LDL. In recent years, though, many guidelines have moved toward accepting non-fasting lipid panels for routine screening. How much difference does it actually make?

A study comparing fasting and non-fasting lipid values found that triglycerides were about 16% higher in the non-fasting state, but the effect on calculated LDL was more modest, around 5% lower.¹⁴ Total cholesterol and HDL barely budged. For screening purposes, a 5% shift in calculated LDL is often acceptable, which is why non-fasting panels have gained favor. But if you are near a treatment threshold, or if your triglycerides tend to run high, a fasting draw gives the formula its best shot at accuracy. This is also one reason non-HDL cholesterol (total cholesterol minus HDL) is sometimes recommended as an alternative metric: it does not require fasting and is not affected by the triglyceride estimation problem at all.

Populations Where the Calculation Gets Trickier

Certain groups of patients consistently trip up the Friedewald formula. People with type 2 diabetes are a prominent example. Their lipid profiles often include moderately elevated triglycerides and changes in lipoprotein composition that shift the triglyceride-to-VLDL ratio away from the assumed one-fifth. In a study of Egyptian patients with type 2 diabetes, Friedewald underestimated LDL with a bias of about 4 mg/dL compared to direct measurement, and the gap widened in those with poorly controlled blood sugar. The Martin-Hopkins equation eliminated this bias and performed with much better sensitivity and specificity.¹⁵

A study in Singaporean patients with type 2 diabetes found that when directly measured LDL was used as the reference standard, all three calculated equations showed some degree of discordance, even at low triglyceride levels. But the differences grew sharply as triglycerides climbed. At triglyceride levels above roughly 400 mg/dL, the discordance rate for the Martin-Hopkins equation reached nearly 38%, suggesting that no calculation is a reliable substitute for direct measurement in this range.¹⁶

Metabolic syndrome presents similar challenges. People meeting criteria for metabolic syndrome (a cluster of high triglycerides, low HDL, abdominal obesity, high blood sugar, and elevated blood pressure) showed significantly larger gaps between Friedewald-calculated LDL and values from other estimation formulas than people without the syndrome.¹⁷ In patients without metabolic syndrome, the various formulas agreed much more closely. The pattern is consistent: when the lipid profile is “textbook normal,” the Friedewald formula works fine. When it is not, accuracy degrades.

Children and people with familial hypercholesterolemia (an inherited condition causing very high LDL from birth) also deserve mention. In children, calculated LDL values using the Friedewald formula tend to run lower than directly measured values. In a study of both healthy and dyslipidemic children, Friedewald was lower than direct measurement in about three-quarters of cases, and a meaningful proportion of children near borderline-high thresholds would be misclassified by calculated values.¹⁸ In a registry of patients with familial hypercholesterolemia, the Friedewald equation showed lower rates of target achievement than the Martin-Hopkins equation, meaning Friedewald made it look like fewer patients were at goal when in fact their LDL may have been somewhat lower than estimated.¹⁹

Familial dysbetalipoproteinemia, a rarer genetic condition that causes accumulation of abnormal remnant lipoproteins, is an extreme case. In these patients, the standard particle separation assumptions built into any calculation method break down, and all four major approaches showed considerable over- or underestimation compared to ultracentrifugation.²⁰ For these patients, calculated or even directly measured LDL may be unreliable, and clinicians often rely on other markers instead.

Why Some Experts Prefer ApoB or Non-HDL Cholesterol

All the issues above stem from the same root problem: LDL cholesterol is the mass of cholesterol inside LDL particles, and estimating that mass requires assumptions about how cholesterol is distributed across lipoproteins. Some researchers argue that counting the particles themselves is a better approach to assessing cardiovascular risk. Every LDL particle, along with every VLDL and IDL particle, carries exactly one molecule of a protein called apolipoprotein B. Measuring apoB in the blood therefore gives a direct count of all atherogenic particles, regardless of how much cholesterol each one happens to carry.²¹

Multiple expert panels have concluded that apoB can be measured more accurately, more precisely, and more consistently than LDL cholesterol. The reason is definitional: apoB is a single molecule that can be quantified directly, while LDL cholesterol is the mass of a substance within a particle population defined by density, which makes it inherently harder to pin down.²² ApoB is especially useful in patients where LDL cholesterol is unreliable or misleading, including those with diabetes, metabolic syndrome, high triglycerides, or very low LDL values.²¹

Non-HDL cholesterol is a simpler alternative that avoids the triglyceride problem entirely. It is calculated as total cholesterol minus HDL cholesterol, which means it captures all the cholesterol in LDL, VLDL, IDL, and remnant particles together, without needing a separate VLDL estimate. Since it skips the triglyceride-divided-by-5 step, it is not distorted by fed vs. fasting state or by high triglycerides. For many clinicians, non-HDL cholesterol is the easiest workaround: it uses numbers already on the lipid panel, adds no cost, and gives a broader measure of atherogenic cholesterol that sidesteps the calculation problems that plague LDL.

The Cost Angle

Given all the limitations of calculating LDL, you might wonder why labs don’t just measure it directly every time. Cost is a major factor. A standard lipid panel (which gives you total cholesterol, HDL, and triglycerides, with LDL calculated for free by the formula) is significantly cheaper than ordering a direct LDL test as a standalone. One cost-effectiveness study in a hospital stroke-workup setting found that switching from a full lipid panel to a direct LDL-only measurement for inpatients saved about a third of the lipid-testing budget over three years.²³ But that study was looking at a specific hospital context where the other lipid panel components were not needed for immediate decision-making. For general outpatient screening, the full lipid panel provides HDL and triglyceride information that clinicians use for broader risk assessment, which makes the calculated approach the sensible default for most patients.

In much of the world, direct LDL assays are simply not available or not affordable. The calculated approach requires no special reagent or equipment beyond what any basic chemistry analyzer provides. This accessibility is the Friedewald formula’s enduring advantage, and it is a major reason why newer, more accurate formulas like Martin-Hopkins and Sampson are so valuable: they improve accuracy without adding any lab cost, since they use the same three input measurements. The improvement is purely in the math.

What Your Lab Is Probably Using Now

If you received a lipid panel from a major clinical lab in the United States in the last few years, there is a good chance your LDL was calculated using the Martin-Hopkins equation rather than the original Friedewald. Several large reference laboratories adopted it after 2020. The Sampson-NIH equation is gaining traction as well, particularly in settings with higher proportions of patients with elevated triglycerides. Outside the U.S., adoption varies widely, and many labs still use Friedewald by default. Your lab report may or may not specify which formula was used. If it simply says “LDL cholesterol (calculated),” you can call the lab and ask. If it says “LDL cholesterol (direct),” the value came from a direct assay rather than any formula.

For most people with triglycerides under 150 mg/dL and LDL above 70 mg/dL, the differences between formulas are small enough to be clinically irrelevant. The calculation method matters most when your LDL is in the range where treatment decisions hinge on whether you are above or below a target, and your triglycerides are elevated. If you are on aggressive lipid-lowering therapy driving your LDL into very low territory, or if your triglycerides tend to run above 200 mg/dL, it is worth knowing how your LDL was determined and whether a different method might give a more reliable number. That conversation with your doctor is straightforward: you don’t need to know the formulas, just whether the calculation method on your lab slip is appropriate for your particular lipid profile.